Developing DMSO Free Cryopreservation Media
We are dedicated to addressing the challenges of cryopreservation in cell therapy workflows. Our innovative formulations are designed to be versatile, safer, and more effective than traditional solutions, providing a cost and time-saving alternative for banking stem cells and other crucial cell types used in various indications.
We are proud to highlight our recent breakthroughs in DMSO-free formulations, outperforming solutions containing DMSO while eliminating concerns of cellular and in vivo toxicity.
Our animal-free solutions are manufactured according to cGMP standards in our ISO 13485:2016 facility, offering simplicity and compatibility with any cell culture workflow without the need for specialized equipment or extensive training.
By enhancing the shelf-life and post-preservation viability of cryopreserved cells, we strive to contribute to the democratization of cell therapies, ensuring successful outcomes in research and clinical studies.
CaseCryo® NON-DMSO “The scientific team at CaseBioscience with its leading cryobiologists, cell biologists, and development biologists aims to bring market disruptive, innovative non-DMSO formulations and improved methods of cryopreservation that offer safer and accessible alternatives in cell and gene therapies” says Chief Scientific Officer.
Through the Case media platform, and a range of media optimization and manufacturing services, we offer advanced cell culture and cryopreservation media solutions for stem and primary cells to support basic, translational, and clinical research, as well as commercial applications.
CaseBioscience is dedicated to developing a comprehensive range of products tailored to various stages of the cell therapy workflow. Our innovative solutions address the unique challenges at each step, from cell culture and expansion to cryopreservation and quality control. Experience a seamless and efficient cell therapy journey with our cutting-edge products designed to support researchers and clinicians at every crucial stage.
There are a few key steps in cell therapy workflows that require cryopreservation, which allows for banking and long-term storage of stem cells and stem-cell derivatives that can be used at multiple time-points and potentially with multiple patients for allogenic therapies. Currently, most laboratories use DMSO based cryopreservation solutions that contain animal serum, human serum or serum derived proteins which can be limiting and undefined.